Baupost Group LLC MA grew its stake in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 9.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,000,000 shares of the biotechnology company’s stock after purchasing an additional 619,481 shares during the period. Atara Biotherapeutics comprises approximately 1.3% of Baupost Group LLC MA’s investment portfolio, making the stock its 23rd largest holding. Baupost Group LLC MA owned 13.02% of Atara Biotherapeutics worth $140,770,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in the business. Manchester Capital Management LLC acquired a new position in shares of Atara Biotherapeutics during the 1st quarter worth approximately $56,000. Aperio Group LLC acquired a new position in shares of Atara Biotherapeutics during the 2nd quarter worth approximately $63,000. Bank of Montreal Can raised its stake in shares of Atara Biotherapeutics by 81.1% during the 2nd quarter. Bank of Montreal Can now owns 8,314 shares of the biotechnology company’s stock worth $167,000 after buying an additional 3,723 shares during the period. Oppenheimer & Co. Inc. raised its stake in shares of Atara Biotherapeutics by 15.2% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 10,132 shares of the biotechnology company’s stock worth $203,000 after buying an additional 1,340 shares during the period. Finally, Virtus ETF Advisers LLC acquired a new position in shares of Atara Biotherapeutics during the 2nd quarter worth approximately $245,000. Institutional investors and hedge funds own 91.79% of the company’s stock.
In related news, Director Eric Dobmeier bought 2,000 shares of the business’s stock in a transaction on Thursday, June 27th. The stock was acquired at an average cost of $19.50 per share, with a total value of $39,000.00. Following the purchase, the director now directly owns 16,000 shares of the company’s stock, valued at $312,000. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 7.00% of the stock is owned by company insiders.
Several research analysts have recently weighed in on ATRA shares. BidaskClub raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 16th. Stifel Nicolaus started coverage on Atara Biotherapeutics in a research note on Wednesday, May 22nd. They issued a “buy” rating and a $41.00 price objective for the company. ValuEngine downgraded Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 17th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $70.00 price objective on shares of Atara Biotherapeutics in a research note on Monday, July 1st. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $36.50.
Shares of ATRA opened at $15.58 on Friday. Atara Biotherapeutics Inc has a 52-week low of $11.89 and a 52-week high of $43.95. The company has a market capitalization of $839.70 million, a PE ratio of -2.96 and a beta of 2.10. The stock has a fifty day simple moving average of $13.71 and a two-hundred day simple moving average of $25.08. The company has a quick ratio of 7.80, a current ratio of 7.80 and a debt-to-equity ratio of 0.06.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.45) by ($0.15). As a group, equities analysts anticipate that Atara Biotherapeutics Inc will post -5.71 earnings per share for the current fiscal year.
Atara Biotherapeutics Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Further Reading: What is an Initial Coin Offering (ICO)?
Receive News & Ratings for Atara Biotherapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Atara Biotherapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.